Milan, Italy (August 27, 2024)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its attendance at 2024 Bolzano Slush’D.

Marco Ferroni, Chief Executive Officer, will be attending the event, held September 3, 2024 in Bolzano, Italy.

Slush’D is a non-profit movement uniting startups, investors, corporate leaders, and institutional representatives, supporting the mission to champion innovation and entrepreneurial spirit among key players in the local, national, and international ecosystem.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.